U.S. markets closed

Aspen Pharmacare Holdings Limited (APNHY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
10.16-0.04 (-0.39%)
At close: 10:20AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.20
Open10.16
Bid0.00 x 0
Ask0.00 x 0
Day's Range10.16 - 10.16
52 Week Range5.54 - 10.64
Volume216
Avg. Volume2,062
Market Cap4.659B
Beta (5Y Monthly)0.82
PE Ratio (TTM)14.70
EPS (TTM)0.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateOct 04, 2018
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reuters

    UPDATE 1-S.Africa's Aspen Pharmacare to supply J&J's COVID-19 vaccine by end-June

    Aspen Pharmacare plans to start supplying Johnson & Johnson COVID-19 vaccine doses from its facility in South Africa before the end of June, its chief executive said on Friday. Stephen Saad told Reuters in an interview that the technology transfer from J&J has "gone very well, and we are now committing (to) commercial supply in our financial year", which ends June 30. Aspen's production timeline for the vaccine is critical for South Africa as the country is relying heavily on J&J's doses to inoculate a significant portion of the 40 million people it is targeting to reach so-called herd immunity.

  • Reuters

    S.Africa's Aspen Pharmacare to supply J&J's COVID-19 vaccine by end-June

    Aspen Pharmacare plans to start supplying Johnson & Johnson COVID-19 vaccine doses from its facility in South Africa before the end of June, its chief executive said on Friday. Stephen Saad told Reuters in an interview that the technology transfer from J&J has "gone very well and we are now committing commercial supply in our financial year." The company has committed 300 million COVID-19 vaccine doses, however the final amount that will be manufactured will depend on demand from J&J, he said.

  • Reuters

    South Africa's Aspen could produce J&J COVID shots by end-March

    Aspen Pharmacare could start production of Johnson & Johnson COVID-19 vaccines in South Africa by late March or early April if all approvals are in place, a senior company executive said. All the vaccines produced will be exported to J&J and will be a part of its global supply inventory, Stavros Nicolaou, Group Senior Executive, Strategic Trade at Aspen, added.